Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Looks To Update National Biotechnology Strategy

This article was originally published in PharmAsia News

Executive Summary

The Japanese government has set up a team to update its 2002 biotechnology strategic outline. The team will discuss topics such as promoting research and development, early commercialization of new technology and raising public awareness. Regenerative medicine and medical devices are also included in the discussions. The team plans to release a midterm report in June. Led by Tasuku Honjo of the Council for Science and Technology, the team consists of researchers and industrial representatives, including Hatsuo Aoki, president of the Japan Pharmaceutical Manufacturers Association. At the first meeting, Minister of State for Science, Technology and Innovation Policy, Fumio Kishida, commented that an industry-government-academia alliance is vital for the advancement of Japan's biotechnology policy. (Click here for more-J apanese language

You may also be interested in...



AHPA Members Report Problems In Raw Material, Other Supplies In Pandemic Survey For USDA

Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.

COVID-19 Partnerships Without Formal Contracts Pose Risks, From Potential Liability To IP Issues

Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.

‘Astonishing Results’ Or ‘Outrageous’ Claims? Peter Thomas Roth Fighting Bicoastal Class Actions

Plaintiffs against the prestige, “clinical” skin-care company are targeting anti-aging claims on its Rose Stem Cell Bio-Repair line and statements about hyaluronic acid’s ultra-moisturizing capabilities, used to market its Water Drench range. PTR faces false advertising class actions in California and New York federal courts, and the former case appears to be headed for trial.

UsernamePublicRestriction

Register

SC066089

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel